Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update.

Visvanathan K, Fabian CJ, Bantug E, Brewster AM, Davidson NE, DeCensi A, Floyd JD, Garber JE, Hofstatter EW, Khan SA, Katapodi MC, Pruthi S, Raab R, Runowicz CD, Somerfield MR.

J Clin Oncol. 2019 Sep 3:JCO1901472. doi: 10.1200/JCO.19.01472. [Epub ahead of print]

PMID:
31479306
2.

Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.

Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK.

J Clin Oncol. 2019 Aug 28:JCO1901304. doi: 10.1200/JCO.19.01304. [Epub ahead of print]

PMID:
31461380
3.

Clinical factors associated with adherence to aerobic and resistance physical activity guidelines among cancer prevention patients and survivors.

Coletta AM, Marquez G, Thomas P, Thoman W, Bevers T, Brewster AM, Hawk E, Basen-Engquist K, Gilchrist SC.

PLoS One. 2019 Aug 1;14(8):e0220814. doi: 10.1371/journal.pone.0220814. eCollection 2019.

4.

High-Intensity Interval Training is Feasible in Women at High Risk for Breast Cancer.

Coletta AM, Brewster AM, Chen M, Li Y, Bevers TB, Basen-Engquist K, Gilchrist SC.

Med Sci Sports Exerc. 2019 Jun 20. doi: 10.1249/MSS.0000000000002048. [Epub ahead of print]

PMID:
31269007
5.

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.

Lim B, Murthy RK, Lee J, Jackson SA, Iwase T, Davis DW, Willey JS, Wu J, Shen Y, Tripathy D, Alvarez R, Ibrahim NK, Brewster AM, Barcenas CH, Brown PH, Giordano SH, Moulder SL, Booser DJ, Moscow JA, Piekarz R, Valero V, Ueno NT.

Br J Cancer. 2019 Jun;120(12):1105-1112. doi: 10.1038/s41416-019-0473-y. Epub 2019 May 17.

PMID:
31097774
6.

Oncologists' Attitudes and Practice of Addressing Diet, Physical Activity, and Weight Management With Patients With Cancer: Findings of an ASCO Survey of the Oncology Workforce.

Ligibel JA, Jones LW, Brewster AM, Clinton SK, Korde LA, Oeffinger KC, Bender CM, Tan W, Merrill JK, Katta S, Alfano CM.

J Oncol Pract. 2019 Jun;15(6):e520-e528. doi: 10.1200/JOP.19.00124. Epub 2019 May 16.

PMID:
31095436
7.

Demographic, clinical, and geographical factors associated with lack of receipt of physician recommended chemotherapy in women with breast cancer in Texas.

Thomas PS, Class CA, Gandhi TR, Bambhroliya A, Do KA, Brewster AM.

Cancer Causes Control. 2019 Apr;30(4):409-415. doi: 10.1007/s10552-019-01151-9. Epub 2019 Mar 13.

PMID:
30868330
8.

Who should get a contralateral prophylactic mastectomy for breast cancer?

Bedrosian I, Parker PA, Brewster AM.

Cancer. 2019 May 1;125(9):1400-1403. doi: 10.1002/cncr.31915. Epub 2019 Jan 15. No abstract available.

PMID:
30645775
9.

Discussions about contralateral prophylactic mastectomy among surgical oncology providers and women with sporadic breast cancer: a content analysis.

D'Agostino TA, Brewster AM, Peterson SK, Bedrosian I, Parker PA.

Transl Behav Med. 2018 Dec 18. doi: 10.1093/tbm/iby098. [Epub ahead of print]

PMID:
30561744
10.

A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β.

Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC Jr, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B.

Invest New Drugs. 2018 Dec;36(6):1103-1109. doi: 10.1007/s10637-018-0672-z. Epub 2018 Oct 11.

PMID:
30311036
11.

Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer.

Parker PA, Peterson SK, Shen Y, Bedrosian I, Black DM, Thompson AM, Nelson JC, DeSnyder SM, Cook RL, Hunt KK, Volk RJ, Cantor SB, Dong W, Brewster AM.

J Clin Oncol. 2018 Sep 1;36(25):2630-2638. doi: 10.1200/JCO.2018.78.6442. Epub 2018 Jul 25.

12.

Impact of acculturation on breast cancer treatment and survivorship care among Mexican American patients in Texas.

Advani P, Bondy M, Thompson PA, Martínez ME, Nodora JN, Vernon SW, Diamond P, Burnett J, Brewster AM.

J Cancer Surviv. 2018 Oct;12(5):659-668. doi: 10.1007/s11764-018-0703-y. Epub 2018 Jul 25.

13.

Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer.

Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT.

JAMA Oncol. 2018 Sep 1;4(9):1207-1213. doi: 10.1001/jamaoncol.2018.1436.

14.

Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer.

Reddy JP, Atkinson RL, Larson R, Burks JK, Smith D, Debeb BG, Ruffell B, Creighton CJ, Bambhroliya A, Reuben JM, Van Laere SJ, Krishnamurthy S, Symmans WF, Brewster AM, Woodward WA.

Breast Cancer Res Treat. 2018 Sep;171(2):283-293. doi: 10.1007/s10549-018-4835-6. Epub 2018 Jun 1.

PMID:
29858753
15.

Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies.

Pande M, Joon A, Brewster AM, Chen WV, Hopper JL, Eng C, Shete S, Casey G, Schumacher F, Lin Y, Harrison TA, White E, Ahsan H, Andrulis IL, Whittemore AS, John EM, Ko Win A, Makalic E, Schmidt DF, Kapuscinski MK, Ochs-Balcom HM, Gallinger S, Jenkins MA, Newcomb PA, Lindor NM, Peters U, Amos CI, Lynch PM.

PLoS One. 2018 Apr 26;13(4):e0196245. doi: 10.1371/journal.pone.0196245. eCollection 2018.

16.

A System-Level Approach to Improve the Uptake of Antiestrogen Preventive Therapy among Women with Atypical Hyperplasia and Lobular Cancer In Situ.

Brewster AM, Thomas P, Brown P, Coyne R, Yan Y, Checka C, Middleton L, Do KA, Bevers T.

Cancer Prev Res (Phila). 2018 May;11(5):295-302. doi: 10.1158/1940-6207.CAPR-17-0314. Epub 2018 Apr 4.

17.

Alcohol and Cancer: A Statement of the American Society of Clinical Oncology.

LoConte NK, Brewster AM, Kaur JS, Merrill JK, Alberg AJ.

J Clin Oncol. 2018 Jan 1;36(1):83-93. doi: 10.1200/JCO.2017.76.1155. Epub 2017 Nov 7.

PMID:
29112463
18.

Lack of Breastfeeding History in Parous Women with Inflammatory Breast Cancer Predicts Poor Disease-Free Survival.

Stecklein SR, Reddy JP, Wolfe AR, Lopez MS, Fouad TM, Debeb BG, Ueno NT, Brewster AM, Woodward WA.

J Cancer. 2017 Jul 1;8(10):1726-1732. doi: 10.7150/jca.20095. eCollection 2017.

19.

Racial Differences in 20-Year Cardiovascular Mortality Risk Among Childhood and Young Adult Cancer Survivors.

Berkman AM, Brewster AM, Jones LW, Yu J, Lee JJ, Peng SA, Crocker A, Ater JL, Gilchrist SC.

J Adolesc Young Adult Oncol. 2017 Sep;6(3):414-421. doi: 10.1089/jayao.2017.0024. Epub 2017 May 22.

20.

A pilot randomized trial to prevent sexual dysfunction in postmenopausal breast cancer survivors starting adjuvant aromatase inhibitor therapy.

Advani P, Brewster AM, Baum GP, Schover LR.

J Cancer Surviv. 2017 Aug;11(4):477-485. doi: 10.1007/s11764-017-0606-3. Epub 2017 Feb 22.

PMID:
28229275
21.

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN.

J Clin Oncol. 2017 Apr 1;35(10):1049-1060. doi: 10.1200/JCO.2015.63.1010. Epub 2017 Jan 30.

22.

Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033).

Davies KR, Brewster AM, Bedrosian I, Parker PA, Crosby MA, Peterson SK, Shen Y, Volk RJ, Cantor SB.

Breast Cancer Res. 2016 Sep 20;18(1):93. doi: 10.1186/s13058-016-0752-y.

23.

TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.

Mitri Z, Nanda R, Blackwell K, Costelloe CM, Hood I, Wei C, Brewster AM, Ibrahim NK, Koenig KB, Hortobagyi GN, Van Poznak C, Rimawi MF, Moulder-Thompson S; Translational Breast Cancer Research Consortium.

Clin Cancer Res. 2016 Dec 1;22(23):5706-5712. Epub 2016 May 10.

24.

Epidemiological risk factors associated with inflammatory breast cancer subtypes.

Atkinson RL, El-Zein R, Valero V, Lucci A, Bevers TB, Fouad T, Liao W, Ueno NT, Woodward WA, Brewster AM.

Cancer Causes Control. 2016 Mar;27(3):359-66. doi: 10.1007/s10552-015-0712-3. Epub 2016 Jan 21.

25.

Barriers to the Use of Breast Cancer Risk Reduction Therapies.

Bambhroliya A, Chavez-MacGregor M, Brewster AM.

J Natl Compr Canc Netw. 2015 Jul;13(7):927-35. Review.

PMID:
26150584
26.

Prospective Study of Surgical Decision-making Processes for Contralateral Prophylactic Mastectomy in Women With Breast Cancer.

Parker PA, Peterson SK, Bedrosian I, Crosby MA, Shen Y, Black DM, Babiera G, Kuerer HM, Ying J, Dong W, Cantor SB, Brewster AM.

Ann Surg. 2016 Jan;263(1):178-83. doi: 10.1097/SLA.0000000000001216.

27.

Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy.

Davies KR, Cantor SB, Brewster AM.

Int J Womens Health. 2015 Feb 4;7:181-7. doi: 10.2147/IJWH.S52380. eCollection 2015. Review.

28.

Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.

Brewster AM, Chavez-MacGregor M, Brown P.

Lancet Oncol. 2014 Dec;15(13):e625-e634. doi: 10.1016/S1470-2045(14)70364-X. Epub 2014 Nov 24. Review.

29.

Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.

Pande M, Bondy ML, Do KA, Sahin AA, Ying J, Mills GB, Thompson PA, Brewster AM.

Breast Cancer Res Treat. 2014 Sep;147(2):381-7. doi: 10.1007/s10549-014-3081-9. Epub 2014 Aug 10.

30.

Telemedicine and telesurgery in cancer care: inaugural conference at MD Anderson Cancer Center.

Satcher RL, Bogler O, Hyle L, Lee A, Simmons A, Williams R, Hawk E, Matin S, Brewster AM.

J Surg Oncol. 2014 Sep;110(4):353-9. doi: 10.1002/jso.23652. Epub 2014 May 29. Review.

PMID:
24889208
31.

Cost of contralateral prophylactic mastectomy.

Deshmukh AA, Cantor SB, Crosby MA, Dong W, Shen Y, Bedrosian I, Peterson SK, Parker PA, Brewster AM.

Ann Surg Oncol. 2014 Sep;21(9):2823-30. doi: 10.1245/s10434-014-3759-6. Epub 2014 May 9.

32.

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.

Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F.

Ann Oncol. 2014 Jun;25(6):1122-7. doi: 10.1093/annonc/mdu124. Epub 2014 Mar 24.

33.

Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer.

Liu Y, Zhou R, Baumbusch LO, Tsavachidis S, Brewster AM, Do KA, Sahin A, Hortobagyi GN, Taube JH, Mani SA, Aarøe J, Wärnberg F, Børresen-Dale AL, Mills GB, Thompson PA, Bondy ML.

Breast Cancer Res Treat. 2014 Jan;143(1):189-201. doi: 10.1007/s10549-013-2796-3. Epub 2013 Dec 4.

34.

Ethnic disparities in adherence to breast cancer survivorship surveillance care.

Advani PS, Ying J, Theriault R, Melhem-Bertrand A, Moulder S, Bedrosian I, Tereffe W, Black S, Pini TM, Brewster AM.

Cancer. 2014 Mar 15;120(6):894-900. doi: 10.1002/cncr.28490. Epub 2013 Nov 20.

35.

Genetic variant rs16430 6bp > 0bp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in non-Hispanic white women aged ≤ 55 years.

Guan X, Liu H, Ju J, Li Y, Li P, Wang LE, Brewster AM, Buchholz TA, Arun BK, Wei Q, Liu Z.

Mol Carcinog. 2015 Apr;54(4):281-90. doi: 10.1002/mc.22097. Epub 2013 Oct 26.

36.

Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency.

Atkinson RL, Yang WT, Rosen DG, Landis MD, Wong H, Lewis MT, Creighton CJ, Sexton KR, Hilsenbeck SG, Sahin AA, Brewster AM, Woodward WA, Chang JC.

Breast Cancer Res. 2013;15(5):R77.

37.

An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.

Esteva FJ, Franco SX, Hagan MK, Brewster AM, Somer RA, Williams W, Florance AM, Turner S, Stein S, Perez A.

Oncologist. 2013 Jun;18(6):661-6. doi: 10.1634/theoncologist.2012-0129. Epub 2013 May 22.

38.

The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes.

Bayraktar S, Thompson PA, Yoo SY, Do KA, Sahin AA, Arun BK, Bondy ML, Brewster AM.

Oncologist. 2013;18(5):493-500. doi: 10.1634/theoncologist.2012-0419. Epub 2013 May 1.

39.

Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early stage breast cancer.

Murray JL, Thompson P, Yoo SY, Do KA, Pande M, Zhou R, Liu Y, Sahin AA, Bondy ML, Brewster AM.

Breast Cancer Res Treat. 2013 Apr;138(3):917-24. doi: 10.1007/s10549-013-2445-x. Epub 2013 Mar 26.

40.

Genetic variants in the vitamin D pathway and breast cancer disease-free survival.

Pande M, Thompson PA, Do KA, Sahin AA, Amos CI, Frazier ML, Bondy ML, Brewster AM.

Carcinogenesis. 2013 Mar;34(3):587-94. doi: 10.1093/carcin/bgs369. Epub 2012 Nov 24.

41.

Impact of race and ethnicity on features and outcome of ductal carcinoma in situ of the breast.

Bailes AA, Kuerer HM, Lari SA, Jones LA, Brewster AM.

Cancer. 2013 Jan 1;119(1):150-7. doi: 10.1002/cncr.27707. Epub 2012 Jun 26.

42.

Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status.

Brewster AM, Bedrosian I, Parker PA, Dong W, Peterson SK, Cantor SB, Crosby M, Shen Y.

Cancer. 2012 Nov 15;118(22):5637-43. doi: 10.1002/cncr.27574. Epub 2012 Apr 19.

43.

Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer.

Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU.

J Clin Oncol. 2012 Mar 20;30(9):930-5. doi: 10.1200/JCO.2011.36.2079. Epub 2012 Feb 13.

PMID:
22331946
44.

Gamma-ray-induced mutagen sensitivity and risk of sporadic breast cancer in young women: a case-control study.

Wang LE, Han CH, Xiong P, Bondy ML, Yu TK, Brewster AM, Shete S, Arun BK, Buchholz TA, Wei Q.

Breast Cancer Res Treat. 2012 Apr;132(3):1147-55. doi: 10.1007/s10549-011-1940-1. Epub 2012 Jan 5.

45.

Chemoprevention for breast cancer: overcoming barriers to treatment.

Brewster AM, Davidson NE, McCaskill-Stevens W.

Am Soc Clin Oncol Educ Book. 2012:85-90. doi: 10.14694/EdBook_AM.2012.32.85.

PMID:
24451714
46.

Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer.

Thompson PA, Brewster AM, Kim-Anh D, Baladandayuthapani V, Broom BM, Edgerton ME, Hahn KM, Murray JL, Sahin A, Tsavachidis S, Wang Y, Zhang L, Hortobagyi GN, Mills GB, Bondy ML.

PLoS One. 2011;6(8):e23543. doi: 10.1371/journal.pone.0023543. Epub 2011 Aug 12.

47.

The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers.

Brewster AM, Etzel C, Zhou R, Wong Y, Edge S, Blayney DW, Wilson J, Hudis C, Ottesen R, Hughes ME, Weeks JC, Theriault RL.

Breast Cancer Res Treat. 2011 Dec;130(3):897-904. doi: 10.1007/s10549-011-1516-0. Epub 2011 Aug 2.

48.

Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival.

Brewster AM, Thompson P, Sahin AA, Do K, Edgerton M, Murray JL, Tsavachidis S, Zhou R, Liu Y, Zhang L, Mills G, Bondy M.

Cancer Prev Res (Phila). 2011 Oct;4(10):1609-16. doi: 10.1158/1940-6207.CAPR-10-0361. Epub 2011 Jul 27.

49.

Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer.

Brewster AM, Parker PA.

Oncologist. 2011;16(7):935-41. doi: 10.1634/theoncologist.2011-0022. Epub 2011 Jun 14. Review.

50.

What can we learn about disease etiology from case-case analyses? Lessons from breast cancer.

Martínez ME, Cruz GI, Brewster AM, Bondy ML, Thompson PA.

Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2710-4. doi: 10.1158/1055-9965.EPI-10-0742. Epub 2010 Sep 24. Review. No abstract available.

Supplemental Content

Loading ...
Support Center